Sugi Predict

Sugi Predict / Compounds / SCHEMBL4976340

SCHEMBL4976340

SCHEMBL4976340

COc1ccc(CCl)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 3/20 0.67
▸ KMT2A Q03164 4/20 0.64
▸ MEN1 O00255 3/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ CA2 P00918 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ MAPT P10636 2/20 0.47
▸ KDM1A O60341 1/20 0.47
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ GFER P55789 1/20 0.47
▸ CSNK2A1 P68400 3/20 0.46
▸ GAA P10253 2/20 0.46
▸ PDE5A O76074 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1373688 0.85 KMT2A (0.57) TTRKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2974160 0.85 TTR (0.60) TTRKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL31285935 0.85 TTR (0.60) TTRKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL185845 0.84 CA2 (0.68) TTRALDH1A1CA2MAPTPOLB
SCHEMBL30074670 0.84 CA2 (0.68) TTRALDH1A1CA2MAPTPOLB
SCHEMBL1015099 0.83 KMT2A (0.56) TTRKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2097147 0.83 ALDH1A1 (0.56) TTRKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL365268 0.83 KMT2A (0.65) TTRKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL1373686 0.83 ALDH1A1 (0.56) TTRKMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL2097150 0.83 MEN1 (0.56) TTRKMT2AMEN1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105712893-A 3-chloro-4-methoxy benzyl amine synthetic method 重庆安格龙翔医药科技有限公司 2016-06-29 — — CN claimed
CN-105712891-A Method used for preparing high purity 3-chloro-4-methoxybenzylamine 重庆安格龙翔医药科技有限公司 2016-06-29 — — CN claimed
CN-104557730-A Preparation method of avanafil key intermediate JIANGSU JIAYI PHARMACEUTICAL CO LTD 2015-04-29 — — CN claimed
US-20260109674-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY THE UNIVERSITY OF TOLEDO (US) 2026-04-23 — — US disclosed
WO-2024105159-A1 LIGANDS OF THE M6A-RNA READERS UNIVERSITY OF ZURICH (CH) 2024-05-23 — — WO disclosed
WO-2024102245-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY THE UNIVERSITY OF TOLEDO (US) 2024-05-16 — — WO disclosed
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds IDEAYA BIOSCIENCES, INC. (US) 2023-02-21 — — US disclosed
US-11332459-B2 Benzimidazole derivatives and their uses TEIJIN PHARMA LIMITED (JP) 2022-05-17 — — US disclosed
CN-109320413-B Preparation method of phenylacetic acid compound 江苏联化科技有限公司 2021-07-30 — — CN disclosed
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2020-10-01 — — US disclosed
WO-2019067442-A1 DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS IDEAYA BIOSCIENCES, INC. (US) 2019-04-04 — — WO disclosed
US-5583238-A Method for making intermediates useful in synthesis of retroviral protease inhibitors G. D. SEARLE & CO. (US) 1996-12-10 — — US disclosed
EP-0730570-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1996-09-11 — — EP disclosed
EP-0641333-B1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS SEARLE & CO (US) 1996-08-14 — — EP disclosed
WO-1995014653-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1995-06-01 — — WO disclosed
EP-0641333-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS. SEARLE & CO (US) 1995-03-08 — — EP disclosed
WO-1993023388-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1993-11-25 — — WO disclosed
US-4221919-A Antiinflammatory substituted phenylacetic acids SPOFA, UNITED PHARMACEUTICAL WORKS (CS) 1980-09-09 — — US disclosed
US-4185992-A Imidazole derivatives MAY & BAKER LIMITED (GB) 1980-01-29 — — US disclosed
US-3933947-A INSECTICIDE, MITICIDE, NEMATOCIDE BAYER AKTIENGESELLSCHAFT (DT) 1976-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES TRPC6, TRPV6, TRPM6 TTR 4373/4885KMT2A 3145/4885MEN1 3422/4885
US-20260109674-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY CHRM5, CHRM3, CHRNA3 TTR 1315/4885KMT2A 3712/4885MEN1 4117/4885
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds DHFR, CYC1, CYCS TTR 486/4885KMT2A 2359/4885MEN1 1635/4885
US-11332459-B2 Benzimidazole derivatives and their uses TRPC6, TRPV6, TRPM6 TTR 4373/4885KMT2A 3145/4885MEN1 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.